Tesamorelin (Trans-3-hexenoyl-GHRH 1-44 amide)

A stabilized 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoyl modification, studied in metabolic and body-composition research models.

Request a Quote Request a COA

CAS Number

218949-48-5

Sequence

trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

Molecular Formula

C221H366N72O67S

Molecular Weight

5135.9 g/mol

Purity

≥98% (HPLC)

Form

Lyophilized powder

Vial Content

10mg per vial

Documentation

COA & HPLC Analysis

See our quality assurance & testing process ›

Overview

Tesamorelin is a synthetic analog of the full-length 44-amino-acid growth-hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoyl group to improve resistance to enzymatic degradation. It is among the most extensively studied GHRH analogs in the peer-reviewed literature. Peptide Factory supplies Tesamorelin as a lyophilized powder for laboratory research applications only.

Research Background

Native GHRH(1-44) is rapidly cleaved by DPP-4 in circulation. The hexenoyl modification in Tesamorelin extends its research half-life while preserving high-affinity binding to the GHRH receptor on pituitary somatotrophs. Research groups have used Tesamorelin extensively as a tool compound for studying the GH/IGF-1 axis and its downstream effects on lipid and body-composition metabolism in both animal and human clinical research contexts.

Studied Applications

Peer-reviewed research on Tesamorelin has examined:

GH/IGF-1 axis research — studies characterizing dose-dependent stimulation of endogenous growth hormone pulsatility and downstream IGF-1 production.
Visceral adipose tissue research — clinical and preclinical research has investigated GHRH-axis stimulation in relation to visceral fat metabolism and lipid markers.
Metabolic and lipid research — studies have examined the relationship between GHRH receptor agonism and circulating triglyceride and cholesterol profiles in research cohorts.

Peptide Factory’s Tesamorelin is supplied strictly for laboratory and analytical research use — not for clinical administration, compounding, or personal use.

Storage & Handling

Store lyophilized Tesamorelin at -20°C, protected from light and moisture. See our storage and handling guidance for reconstitution protocols.

References

Falutz, J. et al. “Effects of tesamorelin on visceral fat and liposuppression markers.” N. Engl. J. Med. research literature.
Stanley, T. L. et al. GHRH analog research in metabolic studies.
Fourman, L. T. et al. Tesamorelin and lipid metabolism research review.

For Research Use Only — Not for Human Consumption.

Frequently Asked

How does Tesamorelin differ from CJC-1295 (no DAC)?

Tesamorelin is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoyl modification for stability, whereas CJC-1295 (no DAC) is a 29-amino-acid truncated analog. Both are studied as GHRH receptor agonists but differ in structure and research history.

Is Tesamorelin an approved pharmaceutical?

A tesamorelin-based product has received regulatory approval in some jurisdictions for a specific indication. Peptide Factory supplies Tesamorelin exclusively as a research-grade compound for laboratory use — not as a clinical or consumer product.

Related Products

For Research Use Only — Not for Human Consumption